DDInter1491 DDInter875
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Pomalidomide {u} (Compound) binds {v} (Gene) TNF
Pomalidomide {u} (Compound) causes {v} (Side Effect) Dermatitis
Pomalidomide (Compound) resembles Lenalidomide (Compound)
Pomalidomide (Compound) binds TNF (Gene)
Pomalidomide (Compound) causes Dermatitis (Side Effect)